isoproterenol has been researched along with Hypertension, Pulmonary in 81 studies
Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.
isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.
Hypertension, Pulmonary: Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A two-year-old child dying of pulmonary hypertension and cor pulmonale secondary to bronchopulmonary dysplasia, was demonstrated to have reactive pulmonary hypertension in response to 100% oxygen and isoproterenol infusion." | 9.06 | Treatment of pulmonary hypertension with diltiazem in a child with bronchopulmonary dysplasia. ( Bingham, WT; Duncan, WJ; Kasian, GF; Mersal, A; Ninan, A; Sankaran, K; Tyrrell, MJ, 1988) |
| " Nifedipine depressed Qt significantly in this glass-bead embolization model of acute pulmonary hypertension." | 7.68 | Hemodynamic profiles of prostaglandin E1, isoproterenol, prostacyclin, and nifedipine in experimental porcine pulmonary hypertension. ( McLean, R; Pearl, RG; Prielipp, RC; Rosenthal, MH, 1991) |
| "After antenatal induction of diaphragmatic hernias in fetal lambs, prostaglandins D2, E1, and I2 were compared to tolazoline, or isoprenaline, for the treatment of pulmonary hypertension." | 7.68 | Pulmonary hypertension in lambs with congenital diaphragmatic hernia: vasodilator prostaglandins, isoprenaline, and tolazoline. ( Barker, AP; Ford, WD; Lee, CM; Sen, S, 1990) |
| " We investigated effects of norepinephrine (11 dogs) and isoproterenol (seven dogs) on the pulmonary vascular PAP-CO relationship in a model of pulmonary hypertension produced by injection of autologous blood clots." | 7.67 | Treatment of canine pulmonary hypertension: effects of norepinephrine and isoproterenol on pulmonary vascular pressure-flow characteristics. ( Boiteau, P; Dasilva, H; Ducas, J; Duval, D; Prewitt, RM, 1987) |
| " Sublingual isoproterenol (Isuprel) has been effective in a few cases but the every-two-hour dosage schedule is inconvenient on a long-term basis." | 5.26 | Primary pulmonary hypertension. Responses to indomethacin, terbutaline, and isoproterenol. ( Person, B; Proctor, RJ, 1979) |
| "A two-year-old child dying of pulmonary hypertension and cor pulmonale secondary to bronchopulmonary dysplasia, was demonstrated to have reactive pulmonary hypertension in response to 100% oxygen and isoproterenol infusion." | 5.06 | Treatment of pulmonary hypertension with diltiazem in a child with bronchopulmonary dysplasia. ( Bingham, WT; Duncan, WJ; Kasian, GF; Mersal, A; Ninan, A; Sankaran, K; Tyrrell, MJ, 1988) |
| "Rats treated with monocrotaline (MCT) develop pulmonary hypertension." | 3.72 | Mechanical load-dependent regulation of gene expression in monocrotaline-induced right ventricular hypertrophy in the rat. ( Brodde, OE; Hartmann, O; Hasenfuss, G; Kögler, H; Leineweber, K; Nguyen van, P; Schott, P, 2003) |
| "The study consisted of six groups (N=30; five rabbits/group): (1) Control with no pretreatment, monocrotaline injected groups: (solutions were perfused following termination of CPB for 60 min); (2) Control for pulmonary hypertension (PHT); (3) isoproteronol; (4) VIP 10(-6) M; (5) VIP 10(-5) M; (6) nitroglycerine." | 3.71 | The effects of vasoactive intestinal peptide on monocrotaline induced pulmonary hypertensive rabbits following cardiopulmonary bypass: a comparative study with isoproteronol and nitroglycerine. ( Chang, D; Gunaydin, S; Hagino, I; Imai, Y; Seo, K; Shinoka, T; Takanashi, Y, 2002) |
| "To investigate the role of endothelium-derived relaxing factor (EDRF) in the regulation of resting pulmonary vascular tone and endothelium-dependent pulmonary vasodilation, we studied the hemodynamic effects of N omega-nitro-L-arginine (a new stereospecific EDRF inhibitor) in 10 spontaneously breathing lambs and then compared the hemodynamic responses to five vasodilators during pulmonary hypertension induced by the infusion of U-46619 (a thromboxane A2 mimetic) or N omega-nitro-L-arginine." | 3.68 | N omega-nitro-L-arginine attenuates endothelium-dependent pulmonary vasodilation in lambs. ( Fineman, JR; Heymann, MA; Soifer, SJ, 1991) |
| " Nifedipine depressed Qt significantly in this glass-bead embolization model of acute pulmonary hypertension." | 3.68 | Hemodynamic profiles of prostaglandin E1, isoproterenol, prostacyclin, and nifedipine in experimental porcine pulmonary hypertension. ( McLean, R; Pearl, RG; Prielipp, RC; Rosenthal, MH, 1991) |
| "After antenatal induction of diaphragmatic hernias in fetal lambs, prostaglandins D2, E1, and I2 were compared to tolazoline, or isoprenaline, for the treatment of pulmonary hypertension." | 3.68 | Pulmonary hypertension in lambs with congenital diaphragmatic hernia: vasodilator prostaglandins, isoprenaline, and tolazoline. ( Barker, AP; Ford, WD; Lee, CM; Sen, S, 1990) |
| "In eight anesthetized ventilated goats, the hemodynamic effect of isoproterenol (ISU), dopamine (DOP), norepinephrine (NE), nitroglycerin (NTG), and Ringer's lactate (RL) infusion was evaluated after inducing acute pulmonary hypertension (PHN) to decrease cardiac output." | 3.67 | Treatment of low cardiac output complicating acute pulmonary hypertension in normovolemic goats. ( Mathru, M; Shirakawa, Y; Smith, RA; Sugiura, A; Venus, B, 1986) |
| " We investigated effects of norepinephrine (11 dogs) and isoproterenol (seven dogs) on the pulmonary vascular PAP-CO relationship in a model of pulmonary hypertension produced by injection of autologous blood clots." | 3.67 | Treatment of canine pulmonary hypertension: effects of norepinephrine and isoproterenol on pulmonary vascular pressure-flow characteristics. ( Boiteau, P; Dasilva, H; Ducas, J; Duval, D; Prewitt, RM, 1987) |
| "Vasodilators including isoproterenol, nitroprusside, nitroglycerin, and oxygen were administered to 5 patients with chronic pulmonary hypertension secondary to pulmonary embolism." | 3.66 | Partial reversibility of chronic pulmonary hypertension caused by pulmonary thromboembolic disease. ( Bower, JS; Dantzker, DR, 1981) |
| "The experience derived from the administration of isoproterenol in six patients with pulmonary hypertension of unknown etiology (PAH-UE) is presented." | 3.66 | The role of isoproterenol in pulmonary artery hypertension of unknown etiology (primary): short- and long-term evaluation. ( Bialostozky, D; Lupi-Herrera, E; Sobrino, A, 1981) |
| "We used a mouse model of Chuvash polycythemia (CP), a rare genetic disorder that modestly increases expression of HIF target genes in normoxia, to understand what these effects might be within the heart." | 1.43 | The von Hippel-Lindau Chuvash mutation in mice alters cardiac substrate and high-energy phosphate metabolism. ( Carr, C; Clarke, K; Cole, M; Curtis, MK; Dodd, M; Giles, L; Heather, LC; Robbins, PA; Slingo, M; Tyler, D, 2016) |
| "Pretreatment with indomethacin, isoproterenol, or nifedipine significantly reduced post-air-embolism lung water content to 85." | 1.30 | Pharmacologic modulation of pulmonary vascular permeability during air embolism. ( Huang, KL; Lin, YC, 1997) |
| "Pretreatment with indomethacin or verapamil was also studied, since these drugs block the increase in pulmonary arterial pressure caused by t-bu-OOH." | 1.27 | Pharmacological modification of pulmonary vascular injury: possible role of cAMP. ( Farrukh, IS; Gurtner, GH; Michael, JR, 1987) |
| "Secondary pulmonary hypertension is seen in disorders that either interfere with gas exchange within the lung or in which large portions of the pulmonary vasculature are obliterated." | 1.27 | Therapy of secondary pulmonary hypertension. ( Peil, ML; Rubin, LJ, 1986) |
| "Isosorbide dinitrate was the only drug that elicited any reduction in pulmonary artery pressure; pulmonary vascular resistance decreased modestly." | 1.26 | Vasodilators and prostaglandin inhibitors in primary pulmonary hypertension. ( Bambach, D; Fontana, ME; Hermiller, JB; Huss, P; Leier, CV; Magorien, RD; Thompson, MJ; Unverferth, DV, 1982) |
| "Treatment with isoproterenol and tolazoline was initiated but was unsuccessful: the child died at 18 months." | 1.26 | [Primary pulmonary hypertension in children]. ( Bein, G; Jimenez, E; Lange, L; Lichtenstern-Peters, E; Schachinger, H; Schartl, S; Stoltenburg-Didinger, G, 1982) |
| " Sublingual isoproterenol (Isuprel) has been effective in a few cases but the every-two-hour dosage schedule is inconvenient on a long-term basis." | 1.26 | Primary pulmonary hypertension. Responses to indomethacin, terbutaline, and isoproterenol. ( Person, B; Proctor, RJ, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 55 (67.90) | 18.7374 |
| 1990's | 17 (20.99) | 18.2507 |
| 2000's | 5 (6.17) | 29.6817 |
| 2010's | 4 (4.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Power, AS | 1 |
| Hickey, AJ | 1 |
| Crossman, DJ | 1 |
| Loiselle, DS | 1 |
| Ward, ML | 1 |
| Htet, M | 1 |
| Nally, JE | 1 |
| Shaw, A | 1 |
| Foote, BE | 1 |
| Martin, PE | 1 |
| Dempsie, Y | 1 |
| Stephens, OR | 1 |
| Weiss, K | 1 |
| Frimel, M | 1 |
| Rose, JA | 1 |
| Sun, Y | 1 |
| Asosingh, K | 1 |
| Farha, S | 1 |
| Highland, KB | 1 |
| Prasad, SVN | 1 |
| Erzurum, SC | 1 |
| Slingo, M | 1 |
| Cole, M | 1 |
| Carr, C | 1 |
| Curtis, MK | 1 |
| Dodd, M | 1 |
| Giles, L | 1 |
| Heather, LC | 1 |
| Tyler, D | 1 |
| Clarke, K | 1 |
| Robbins, PA | 1 |
| Kocic, I | 1 |
| Sztormowska, K | 1 |
| Irodova, NL | 1 |
| Krasnikova, TL | 1 |
| Masenko, VP | 1 |
| Kochetov, AG | 1 |
| Lazutkina, VK | 1 |
| Chazova, IE | 1 |
| Kögler, H | 1 |
| Hartmann, O | 1 |
| Leineweber, K | 1 |
| Nguyen van, P | 1 |
| Schott, P | 1 |
| Brodde, OE | 1 |
| Hasenfuss, G | 1 |
| LEE, TD | 1 |
| ROVETI, GC | 1 |
| ROSS, RS | 1 |
| HALMAGYI, DF | 1 |
| STARZECKI, B | 1 |
| MCRAE, J | 1 |
| HORNER, GJ | 1 |
| Tikoff, G | 1 |
| Schmidt, AM | 1 |
| Tsagaris, TJ | 1 |
| Peter, RH | 1 |
| Rubin, L | 1 |
| Rabinovitch, M | 1 |
| Keane, JF | 1 |
| Norwood, WI | 1 |
| Castaneda, AR | 1 |
| Reid, L | 1 |
| Pietro, DA | 1 |
| LaBresh, KA | 1 |
| Shulman, RM | 1 |
| Folland, ED | 1 |
| Parisi, AF | 1 |
| Sasahara, AA | 1 |
| Hogan, RA | 1 |
| Pannarale, G | 2 |
| Gaspardone, A | 2 |
| Acconcia, MC | 2 |
| Valente, A | 2 |
| Dantzker, DR | 2 |
| Bower, JS | 2 |
| Rich, S | 1 |
| Martinez, J | 1 |
| Lam, W | 1 |
| Levy, PS | 1 |
| Rosen, KM | 1 |
| Nakashima, M | 1 |
| Fishman, AP | 1 |
| Pietra, GG | 1 |
| Lupi-Herrera, E | 2 |
| Sandoval, J | 2 |
| Seoane, M | 1 |
| Bialostozky, D | 2 |
| Attie, F | 1 |
| Patten, GA | 1 |
| Klausen, NO | 1 |
| Qvist, J | 1 |
| Brynjolf, I | 1 |
| Munck, O | 1 |
| Sørensen, B | 1 |
| Wiberg-Jørgensen, F | 1 |
| Hermiller, JB | 1 |
| Bambach, D | 1 |
| Thompson, MJ | 1 |
| Huss, P | 1 |
| Fontana, ME | 1 |
| Magorien, RD | 1 |
| Unverferth, DV | 1 |
| Leier, CV | 1 |
| Lichtenstern-Peters, E | 1 |
| Bein, G | 1 |
| Lange, L | 1 |
| Jimenez, E | 1 |
| Schachinger, H | 1 |
| Schartl, S | 1 |
| Stoltenburg-Didinger, G | 1 |
| Sclavo, M | 1 |
| Bucca, C | 1 |
| Rolla, G | 1 |
| Borello, G | 1 |
| Balbi, L | 1 |
| Angelino, PF | 1 |
| Pantano, JA | 1 |
| Rawlings, CA | 1 |
| Klinke, WP | 1 |
| Thomas, D | 1 |
| Drobinski, G | 1 |
| Komajda, M | 1 |
| Grosgogeat, Y | 1 |
| Elkayam, U | 1 |
| Sobrino, A | 1 |
| Myles, PS | 1 |
| Ogata, M | 1 |
| Ohe, M | 1 |
| Shirato, K | 1 |
| Takishima, T | 1 |
| Wang, Y | 1 |
| Enzan, K | 1 |
| Schultz, E | 1 |
| Mitchell, MD | 1 |
| Stavros, F | 1 |
| Staub, NC | 1 |
| Fullerton, DA | 1 |
| Mitchell, MB | 1 |
| Jones, DN | 1 |
| Maki, A | 1 |
| McIntyre, RC | 1 |
| Huang, KL | 1 |
| Lin, YC | 1 |
| Fisher, LE | 1 |
| Cziraki, A | 1 |
| Steinhart, CM | 1 |
| Catravas, JD | 1 |
| Schmiedt, MI | 1 |
| Shettigar, UR | 2 |
| Siddique, M | 1 |
| Barbier, G | 1 |
| Bialow, M | 1 |
| Carranza, S | 1 |
| Eddahibi, S | 1 |
| Raffestin, B | 1 |
| Le Monnier de Gouville, AC | 1 |
| Adnot, S | 1 |
| Ohnishi, M | 1 |
| Oka, M | 1 |
| Muramatsu, M | 1 |
| Sato, K | 1 |
| Kira, S | 1 |
| Fukuchi, Y | 1 |
| Collados, MT | 1 |
| López, S | 1 |
| Massó, FA | 1 |
| Páez, A | 1 |
| Borbolla, JR | 1 |
| Montaño, LF | 1 |
| Decoene, C | 1 |
| Bourzoufi, K | 1 |
| Moreau, D | 1 |
| Narducci, F | 1 |
| Crepin, F | 1 |
| Krivosic-Horber, R | 1 |
| Gunaydin, S | 1 |
| Imai, Y | 1 |
| Takanashi, Y | 1 |
| Seo, K | 1 |
| Hagino, I | 1 |
| Chang, D | 1 |
| Shinoka, T | 1 |
| Person, B | 1 |
| Proctor, RJ | 1 |
| Pelman, MJ | 1 |
| Tiep, BL | 1 |
| Westinghouse, WD | 1 |
| Daoud, FS | 1 |
| Reeves, JT | 1 |
| Kelly, DB | 1 |
| Zapol, WM | 1 |
| Snider, MT | 1 |
| Hultgren, HN | 1 |
| Specter, M | 1 |
| Martin, R | 1 |
| Davies, DH | 1 |
| Bristow, MR | 1 |
| Minobe, W | 1 |
| Rasmussen, R | 1 |
| Larrabee, P | 1 |
| Skerl, L | 1 |
| Klein, JW | 1 |
| Anderson, FL | 1 |
| Murray, J | 1 |
| Mestroni, L | 1 |
| Karwande, SV | 1 |
| Fineman, JR | 2 |
| Heymann, MA | 1 |
| Soifer, SJ | 2 |
| Shaul, PW | 1 |
| Kinane, B | 1 |
| Farrar, MA | 1 |
| Buja, LM | 1 |
| Magness, RR | 1 |
| Prielipp, RC | 2 |
| McLean, R | 1 |
| Rosenthal, MH | 2 |
| Pearl, RG | 2 |
| Crowley, MR | 1 |
| Ford, WD | 1 |
| Sen, S | 1 |
| Barker, AP | 1 |
| Lee, CM | 1 |
| Crombleholme, TM | 1 |
| Adzick, NS | 1 |
| Longaker, MT | 1 |
| Bradley, SM | 1 |
| Duncan, BW | 1 |
| Jennings, R | 1 |
| Verrier, ED | 1 |
| Harrison, MR | 1 |
| Dreyfus, G | 1 |
| Guillemain, R | 1 |
| Amrein, C | 1 |
| Mihaileanu, S | 1 |
| Jebara, V | 1 |
| Blanchard, D | 1 |
| Carpentier, A | 1 |
| Farrukh, IS | 1 |
| Gurtner, GH | 1 |
| Michael, JR | 1 |
| Mathru, M | 1 |
| Venus, B | 1 |
| Smith, RA | 1 |
| Shirakawa, Y | 1 |
| Sugiura, A | 1 |
| Altiere, RJ | 1 |
| Olson, JW | 1 |
| Gillespie, MN | 1 |
| Slomka, F | 1 |
| Salmeron, S | 1 |
| Zetlaoui, P | 1 |
| Cohen, H | 1 |
| Simonneau, G | 1 |
| Samii, K | 1 |
| Kasian, GF | 1 |
| Ninan, A | 1 |
| Duncan, WJ | 1 |
| Bingham, WT | 1 |
| Mersal, A | 1 |
| Tyrrell, MJ | 1 |
| Sankaran, K | 1 |
| Peil, ML | 1 |
| Rubin, LJ | 1 |
| Ducas, J | 1 |
| Duval, D | 1 |
| Dasilva, H | 1 |
| Boiteau, P | 1 |
| Prewitt, RM | 2 |
| Ackroyd, JF | 1 |
| Molloy, DW | 1 |
| Lee, KY | 1 |
| Jones, D | 1 |
| Penner, B | 1 |
| Fried, R | 1 |
| Reid, LM | 1 |
| Bo, G | 1 |
| Hauge, A | 1 |
| Hognestad, J | 1 |
| Kamat, SR | 1 |
| Warrier, NV | 1 |
| Panandikar, SG | 1 |
| Store, SD | 1 |
| Rane, MA | 1 |
| Krempf, M | 1 |
| Vetillard, R | 1 |
| Migueres, J | 1 |
| Jover, A | 1 |
| Bezombes, JP | 1 |
| Garrigues, M | 1 |
| Morris, KN | 1 |
| Stirling, GR | 1 |
| Cooper, E | 1 |
| Talner, NS | 1 |
| Both, A | 1 |
| Silove, ED | 1 |
| Tavernor, WD | 1 |
| Berry, CL | 1 |
| Kraupp, O | 1 |
| Satyanarayana Rao, BN | 1 |
| Moller, JH | 1 |
| Edwards, JE | 1 |
| Keck, EW | 1 |
| Lo, ST | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure[NCT01586156] | 30 participants (Actual) | Interventional | 2012-12-31 | Completed | |||
| Ventilator-induced Right Ventricular Injury During Electrical Impedance Tomography-based Positive End-expiratory Pressure Titration in Patients With Acute Respiratory Distress Syndrome: a Pilot Physiological Study.[NCT05583461] | 20 participants (Anticipated) | Interventional | 2022-10-26 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
We hypothesized that carvedilol would not worsen 6 minute walk distance. (NCT01586156)
Timeframe: 6 months
| Intervention | meters (Mean) | ||
|---|---|---|---|
| baseline | 3 months | 6 months | |
| Escalation-dose Carvedilol | 438 | 438 | 450 |
| Low-fixed-dose Carvedilol | 504 | 504 | 486 |
| Placebo Arm | 404 | 412 | 453 |
We hypothesize that use of carvedilol in patients with PAH will increase beta- adrenergic receptor availability, and this will be measurable as a increase in alprenolol binding over time of drug use. (NCT01586156)
Timeframe: 6 months
| Intervention | abritrary units (Mean) | |
|---|---|---|
| baseline | 6 months | |
| Escalation-dose Carvedilol | 82779 | 83730 |
| Low-fixed-dose Carvedilol | 85230 | 84554 |
| Placebo Arm | 92254 | 79083 |
We hypothesize that use of carvedilol in patients with PAH (Pulmonary Arterial Hypertension) will decrease the cardiac glucose utilization, and this will be measurable as a drop in fasting FDG-PET standardized uptake values of the heart at 6 months as compared to baseline (NCT01586156)
Timeframe: 6 months
| Intervention | standardized uptake value (SUV) (Median) | |
|---|---|---|
| baseline FDG-PET | 6 month FDG-PET | |
| Escalation-dose Carvedilol | 0.9 | 0.7 |
| Low-fixed-dose Carvedilol | 0.6 | 0.6 |
| Placebo Arm | 1.0 | 0.8 |
We hypothesized that carvedilol would be safe and tolerable and thus that Left ventricular cardiac output, a measure of heart function, would not decrease in participants on carvedilol. (NCT01586156)
Timeframe: 6 months
| Intervention | L/min (Mean) | ||
|---|---|---|---|
| baseline | 3 months | 6 months | |
| Escalation-dose Carvedilol | 4.5 | 4.8 | 4.9 |
| Low-fixed-dose Carvedilol | 5.2 | 4.6 | 4.7 |
| Placebo Arm | 4.7 | 4.7 | 4.5 |
We hypothesized that RVSP might decrease in participants on carvedilol. (NCT01586156)
Timeframe: 6 months
| Intervention | mm Hg (Mean) | ||
|---|---|---|---|
| baseline | 3 months | 6 months | |
| Escalation-dose Carvedilol | 63 | 54 | 64 |
| Low-fixed-dose Carvedilol | 63 | 59 | 51 |
| Placebo Arm | 76 | 78 | 66 |
We hypothesized that carvedilol would be safe and tolerable and thus that NT-BNP, a measure of heart failure, would not increase in participants on carvedilol. (NCT01586156)
Timeframe: 6 months
| Intervention | pg/ml (Median) | |||
|---|---|---|---|---|
| baseline | 1 month | 3 months | 6 months | |
| Escalation-dose Carvedilol | 127 | 120 | 169 | 146 |
| Low-fixed-dose Carvedilol | 57 | 92 | 79 | 52 |
| Placebo Arm | 170 | 183 | 152 | 293 |
We hypothesize that use of carvedilol in patients with PAH will increase beta adrenergic receptor function and this will be measurable as an increase in cAMP measured in the urine at 6 months in participants in dose escalation carvedilol. (NCT01586156)
Timeframe: 6 months
| Intervention | umol/g (Median) | |||
|---|---|---|---|---|
| baseline | 1 month | 3 months | 6 months | |
| Escalation-dose Carvedilol | 1.0 | 0.7 | 1.5 | 1.0 |
| Low-fixed-dose Carvedilol | 0.6 | 0.8 | 0.6 | 0.7 |
| Placebo Arm | 1.4 | 1.3 | 1.2 | 1.4 |
4 reviews available for isoproterenol and Hypertension, Pulmonary
| Article | Year |
|---|---|
The pharmacologic control of the pulmonary circulation in pulmonary hypertension.
Topics: Acetylcholine; Adult; Aminophylline; Calcium Channel Blockers; Diazoxide; Female; Humans; Hydralazin | 1984 |
[Early pulmonary hypertension: current therapeutic prospectives].
Topics: Calcium Channel Blockers; Captopril; Diazoxide; Diltiazem; Humans; Hydralazine; Hypertension, Pulmon | 1982 |
Primary pulmonary hypertension.
Topics: Acetylcholine; Aminorex; Diet; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Isoproterenol; | 1980 |
Congestive heart failure in the infant. A functional approach.
Topics: Acid-Base Equilibrium; Arrhythmias, Cardiac; Blood Gas Analysis; Blood Glucose; Diagnosis, Different | 1971 |
2 trials available for isoproterenol and Hypertension, Pulmonary
| Article | Year |
|---|---|
Characterization of von Willebrand factor in primary pulmonary hypertension.
Topics: Adrenergic beta-Agonists; Adult; Antigens; Biomarkers; Blotting, Western; Calcium Channel Blockers; | 1999 |
Treatment of pulmonary hypertension with diltiazem in a child with bronchopulmonary dysplasia.
Topics: Albuterol; Bronchopulmonary Dysplasia; Child, Preschool; Diltiazem; Humans; Hydralazine; Hypertensio | 1988 |
75 other studies available for isoproterenol and Hypertension, Pulmonary
| Article | Year |
|---|---|
Calcium mishandling impairs contraction in right ventricular hypertrophy prior to overt heart failure.
Topics: Animals; Calcium; Heart Failure; Heart Ventricles; Hypertension, Pulmonary; Hypertrophy, Right Ventr | 2018 |
Connexin 43 Plays a Role in Pulmonary Vascular Reactivity in Mice.
Topics: Animals; Connexin 43; Endothelin-1; Female; Gap Junctions; Genotype; Hypertension, Pulmonary; Isopro | 2018 |
Interdependence of hypoxia and β-adrenergic receptor signaling in pulmonary arterial hypertension.
Topics: Adrenergic beta-Antagonists; Animals; Familial Primary Pulmonary Hypertension; Heart Ventricles; Hum | 2019 |
The von Hippel-Lindau Chuvash mutation in mice alters cardiac substrate and high-energy phosphate metabolism.
Topics: Adenosine Triphosphate; Animals; Apoptosis Regulatory Proteins; Aryl Hydrocarbon Receptor Nuclear Tr | 2016 |
Pulmonary hypertension modifies responsiveness of sinoatrial cells of rat hearts to adrenomimetics and activators of ATP-sensitive K+ channels in a gender-dependent way.
Topics: Adrenergic beta-Agonists; Animals; Anti-Arrhythmia Agents; Chromans; Disease Models, Animal; Female; | 2009 |
[Catecholamine levels in plasma and beta2-adrenoreceptor-dependent synthesis of cAMP in lymphocytes of patients with primary pulmonary hypertension].
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Blood Pressure; Catecholamines; Colforsin; Cyclic AMP; | 2002 |
Mechanical load-dependent regulation of gene expression in monocrotaline-induced right ventricular hypertrophy in the rat.
Topics: Actin Cytoskeleton; Adrenergic beta-Agonists; Animals; Biomechanical Phenomena; Body Weight; Calcium | 2003 |
The hemodynamic effects of isoproterenol on pulmonary hypertension in man.
Topics: Hemodynamics; Humans; Hypertension; Hypertension, Pulmonary; Isoproterenol; Male | 1963 |
THE LUNG AS THE MAIN TARGET ORGAN IN THE ACUTE PHASE OF TRANSFUSION REACTION IN SHEEP.
Topics: Animals; Apnea; Blood Group Incompatibility; Blood Transfusion; Heart Function Tests; Heart, Artific | 1963 |
Isoproterenol-induced right ventricular infundibular obstruction. Study in adult with a large ventricular septal defect.
Topics: Adult; Blood Pressure; Cardiac Catheterization; Heart Diseases; Heart Septal Defects, Ventricular; H | 1967 |
Vascular structure in lung tissue obtained at biopsy correlated with pulmonary hemodynamic findings after repair of congenital heart defects.
Topics: Autopsy; Cardiac Output; Cardiac Surgical Procedures; Heart Defects, Congenital; Hemodynamics; Human | 1984 |
Sustained improvement in primary pulmonary hypertension during six years of treatment with sublingual isoproterenol.
Topics: Administration, Oral; Adult; Hemodynamics; Humans; Hypertension, Pulmonary; Isoproterenol; Male | 1984 |
Sublingual isoproterenol for primary pulmonary hypertension.
Topics: Humans; Hypertension, Pulmonary; Isoproterenol | 1984 |
Partial reversibility of chronic pulmonary hypertension caused by pulmonary thromboembolic disease.
Topics: Adult; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Isoproterenol; Male; Middle Aged; Nitr | 1981 |
Reassessment of the effects of vasodilator drugs in primary pulmonary hypertension: guidelines for determining a pulmonary vasodilator response.
Topics: Adult; Blood Pressure; Cardiac Catheterization; Cardiac Output; Diazoxide; Female; Humans; Hydralazi | 1983 |
[Primary pulmonary hypertension: current therapeutic prospectives].
Topics: Calcium Channel Blockers; Diazoxide; Heart Rate; Humans; Hydralazine; Hypertension, Pulmonary; Isopr | 1982 |
[Functional changes in the pulmonary arteries of pulmonary hypertensive rats].
Topics: Adenosine; Animals; Histamine; Hypertension, Pulmonary; In Vitro Techniques; Isoproterenol; Male; Mu | 1982 |
The role of isoproterenol in the preoperative evaluation of high-pressure, high-resistance ventricular septal defect.
Topics: Adolescent; Blood Pressure; Child; Child, Preschool; Female; Heart Septal Defects, Ventricular; Hemo | 1982 |
Gas exchange at rest and during exercise in adults with cystic fibrosis.
Topics: Adolescent; Adult; Arteries; Biomechanical Phenomena; Cystic Fibrosis; Female; Hemodynamics; Humans; | 1982 |
Pulmonary hypertension in a patient with ARDS - a possible side-effect of dopamine treatment.
Topics: Adult; Digoxin; Dopamine; Female; Humans; Hypertension, Pulmonary; Isoproterenol; Respiratory Distre | 1982 |
Vasodilators and prostaglandin inhibitors in primary pulmonary hypertension.
Topics: Adolescent; Adult; Aspirin; Diazoxide; Dipyridamole; Female; Hemodynamics; Humans; Hydralazine; Hype | 1982 |
[Primary pulmonary hypertension in children].
Topics: Cardiac Catheterization; Electrocardiography; Humans; Hypertension, Pulmonary; Infant; Isoproterenol | 1982 |
[Pulmonary hypertension in chronic obstructive lung disease. Hemodynamic changes induced by oxygen, verapamil, and isoproterenol acute administration (author's transl)].
Topics: Aged; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Isoproterenol; Lung Diseases, Obstructi | 1981 |
Isoproterenol in primary pulmonary hypertension.
Topics: Administration, Oral; Adult; Female; Humans; Hypertension, Pulmonary; Isoproterenol; Time Factors | 1980 |
Cardiopulmonary function in the dog with Dirofilaria immitis infection: during infection and after treatment.
Topics: Animals; Blood Pressure; Cardiac Output; Dirofilariasis; Dog Diseases; Dogs; Heart; Heart Rate; Hype | 1980 |
Treatment for primary pulmonary hypertension.
Topics: Diazoxide; Humans; Hypertension, Pulmonary; Isoproterenol; Oxygen Inhalation Therapy; Phentolamine | 1980 |
[Primary pulmonary arterial hypertension. Trial treatment with nifedipine, diazoxide and isoproterenol].
Topics: Diazoxide; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Isoproterenol; Middle | 1980 |
Vasodilator therapy in primary pulmonary hypertension.
Topics: Adult; Diazoxide; Female; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Isoproterenol; | 1981 |
The role of isoproterenol in pulmonary artery hypertension of unknown etiology (primary): short- and long-term evaluation.
Topics: Adolescent; Adult; Child; Electrocardiography; Female; Follow-Up Studies; Hemodynamics; Humans; Hype | 1981 |
Anaesthetic management for laparoscopic sterilisation and termination of pregnancy in a patient with severe primary pulmonary hypertension.
Topics: Abortion, Induced; Adult; Analgesia; Anesthesia, General; Anesthesia, Inhalation; Anesthesia, Intrav | 1994 |
Effects of a combination therapy of anticoagulant and vasodilator on the long-term prognosis of primary pulmonary hypertension.
Topics: Adolescent; Adult; Drug Combinations; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Isoprot | 1993 |
Pulmonary hypertensive response to rabbit blood components in goats: role of thromboxane.
Topics: Animals; Blood Physiological Phenomena; Chlorpheniramine; Female; Goats; Hemodynamics; Hypertension, | 1993 |
Pulmonary vasomotor dysfunction is produced with chronically high pulmonary blood flow.
Topics: Acetylcholine; Adrenergic beta-Agonists; Animals; Arteriovenous Shunt, Surgical; Blood Vessel Prosth | 1996 |
Pharmacologic modulation of pulmonary vascular permeability during air embolism.
Topics: Animals; Capillary Permeability; Cyclooxygenase Inhibitors; Hypertension, Pulmonary; Indomethacin; I | 1997 |
Unaltered pulmonary capillary surface area in the presence of changing arterial resistance.
Topics: Animals; Capillaries; Capillary Resistance; Hypertension, Pulmonary; Isoproterenol; Microcirculation | 1998 |
Unpredictable response to vasodilator therapy in primary pulmonary hypertension.
Topics: Bradycardia; Fatal Outcome; Hemodynamics; Humans; Hypertension, Pulmonary; Infusions, Intravenous; I | 1998 |
Effect of DMPPO, a phosphodiesterase type 5 inhibitor, on hypoxic pulmonary hypertension in rats.
Topics: Allopurinol; Animals; Atrial Natriuretic Factor; Cyclic GMP; Drug Interactions; Hypertension, Pulmon | 1998 |
E4021, a selective phosphodiesterase 5 inhibitor, potentiates the vasodilator effect of inhaled nitric oxide in isolated perfused rat lungs.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; 3',5'-Cyclic-GMP Phosphodiestera | 1999 |
Use of inhaled nitric oxide for emergency Cesarean section in a woman with unexpected primary pulmonary hypertension.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Cesarean Section; Emergency Medical Ser | 2001 |
The effects of vasoactive intestinal peptide on monocrotaline induced pulmonary hypertensive rabbits following cardiopulmonary bypass: a comparative study with isoproteronol and nitroglycerine.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Calcium Channel Blockers; Cardiopulm | 2002 |
Primary pulmonary hypertension. Responses to indomethacin, terbutaline, and isoproterenol.
Topics: Adolescent; Blood Pressure; Female; Humans; Hypertension, Pulmonary; Indomethacin; Isoproterenol; Pr | 1979 |
Isoproterenol in pulmonary hypertension.
Topics: Humans; Hypertension, Pulmonary; Isoproterenol; Male; Middle Aged | 1978 |
Isoproterenol as a potential pulmonary vasodilator in primary pulmonary hypertension.
Topics: Administration, Oral; Adolescent; Adult; Azathioprine; Cardiac Catheterization; Cardiac Output; Diph | 1978 |
Pulmonary hypertension in severe acute respiratory failure.
Topics: Acute Disease; Adolescent; Adult; Blood Pressure; Capillary Resistance; Cardiac Output; Central Veno | 1977 |
Pulmonary hypertension and sleep apnea.
Topics: Apnea; Humans; Hypertension, Pulmonary; Hypoventilation; Isoproterenol; Sleep; Syndrome | 1977 |
Primary pulmonary hypertension; favorable effect of isoproterenol.
Topics: Administration, Oral; Adult; Altitude; Blood Pressure; Drug Evaluation; Humans; Hypertension, Pulmon | 1976 |
Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms.
Topics: Adenylyl Cyclases; Adult; Cardiomyopathy, Dilated; Catecholamines; Female; Heart; Heart Failure; Hum | 1992 |
N omega-nitro-L-arginine attenuates endothelium-dependent pulmonary vasodilation in lambs.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetylcholine; Adenosine Triphos | 1991 |
Prostacyclin production and mediation of adenylate cyclase activity in the pulmonary artery. Alterations after prolonged hypoxia in the rat.
Topics: Adenylyl Cyclases; Animals; Endothelium, Vascular; Enzyme Activation; Epoprostenol; Guanosine Tripho | 1991 |
Hemodynamic profiles of prostaglandin E1, isoproterenol, prostacyclin, and nifedipine in experimental porcine pulmonary hypertension.
Topics: Alprostadil; Animals; Blood Pressure; Cardiac Output; Epoprostenol; Heart Rate; Hemodynamics; Hypert | 1991 |
Effects of vasoactive drugs on thromboxane A2 mimetic-induced pulmonary hypertension in newborn lambs.
Topics: Animals; Animals, Newborn; Cardiovascular Agents; Dobutamine; Dopamine; Hemodynamics; Hypertension, | 1991 |
Pulmonary hypertension in lambs with congenital diaphragmatic hernia: vasodilator prostaglandins, isoprenaline, and tolazoline.
Topics: Animals; Blood Flow Velocity; Blood Pressure; Disease Models, Animal; Hernia, Diaphragmatic; Hernias | 1990 |
Pulmonary vascular resistance in neonatal swine: response to right pulmonary artery occlusion, isoproterenol, and prostaglandin E1.
Topics: Alprostadil; Animals; Animals, Newborn; Constriction; Dose-Response Relationship, Drug; Hypertension | 1990 |
[Limitations of the feasibility of right catheterization in the evaluation for cardiac transplantation].
Topics: Arterioles; Cardiac Catheterization; Dobutamine; Female; Heart Transplantation; Hemodynamics; Humans | 1989 |
Pharmacological modification of pulmonary vascular injury: possible role of cAMP.
Topics: Alprostadil; Animals; Cell Membrane Permeability; Cyclic AMP; Hypertension, Pulmonary; Indomethacin; | 1987 |
Treatment of low cardiac output complicating acute pulmonary hypertension in normovolemic goats.
Topics: Animals; Cardiac Output, Low; Dopamine; Goats; Hemodynamics; Hypertension, Pulmonary; Isoproterenol; | 1986 |
Altered pulmonary vascular smooth muscle responsiveness in monocrotaline-induced pulmonary hypertension.
Topics: Acetylcholine; Angiotensin II; Animals; Dose-Response Relationship, Drug; Hypertension, Pulmonary; I | 1986 |
Primary pulmonary hypertension and pregnancy: anesthetic management for delivery.
Topics: Adult; Anesthesia, Obstetrical; Blood Pressure; Bupivacaine; Female; Humans; Hypertension, Pulmonary | 1988 |
Hemodynamic profiles of prostaglandin E1, isoproterenol, prostacyclin, and nifedipine in vasoconstrictor pulmonary hypertension in sheep.
Topics: Alprostadil; Animals; Drug Evaluation, Preclinical; Epoprostenol; Hemodynamics; Hypertension, Pulmon | 1988 |
Therapy of secondary pulmonary hypertension.
Topics: Bloodletting; Calcium Channel Blockers; Digitalis Glycosides; Diuretics; Humans; Hypertension, Pulmo | 1986 |
Treatment of canine pulmonary hypertension: effects of norepinephrine and isoproterenol on pulmonary vascular pressure-flow characteristics.
Topics: Animals; Arteriovenous Shunt, Surgical; Blood Pressure; Cardiac Catheterization; Cardiac Output; Dog | 1987 |
Sublingual isoprenaline in treatment of primary pulmonary hypertension: discussion paper.
Topics: Administration, Oral; Blood Pressure; Heart Rate; Humans; Hypertension, Pulmonary; Isoproterenol; Mo | 1985 |
Effects of noradrenaline and isoproterenol on cardiopulmonary function in a canine model of acute pulmonary hypertension.
Topics: Animals; Blood Pressure; Cardiac Output; Disease Models, Animal; Dogs; Heart Rate; Hemodynamics; Hyp | 1985 |
The effect of isoproterenol on the development and recovery of hypoxic pulmonary hypertension. A structural and hemodynamic study.
Topics: Animals; Heart; Hemodynamics; Hypertension, Pulmonary; Hypoxia; Isoproterenol; Lung; Lung Volume Mea | 1985 |
Pulmonary hypertension during systemic hypotension. Effects of oxygen breathing and of vasodilators.
Topics: Animals; Blood Circulation; Blood Pressure; Bradykinin; Cardiac Output; Cats; Hypertension, Pulmonar | 1972 |
Pulmonary function in cor pulmonale in India.
Topics: Asthma; Bronchiectasis; Bronchitis; Humans; Hypertension, Pulmonary; Isoproterenol; Lung; Physical E | 1972 |
[Study by means of microcatheterization of the activity of drugs with pharmacodynamic effect on the average pressure in the pulmonary artery].
Topics: Adult; Aged; Amino Alcohols; Blood Pressure; Bronchodilator Agents; Cardiac Catheterization; Female; | 1972 |
A problem in pulmonary hypertension. 1. The clinical course. A clinicopathologic conference from the Division of Pulmonary Diseases, Hahnemann Medical College and Hospital, Philadelphia.
Topics: Acetylcholine; Adult; Cardiac Catheterization; Diagnosis, Differential; Edrophonium; Electrocardiogr | 1974 |
A problem in pulmonary hypertension. 2. The final course and autopsy findings. A clinicopathologic conference from the Division of Pulmonary Diseases, Hahnemann Medical College and Hospital, Philadelphia.
Topics: Acetylcholine; Adult; Arteries; Autopsy; Biopsy; Collateral Circulation; Diagnosis, Differential; Hu | 1974 |
Human cardiac allotransplantation: a case report.
Topics: Adult; Autopsy; Heart Transplantation; Humans; Hypertension, Pulmonary; Isoproterenol; Lung; Male; M | 1969 |
[Therapy of primary pulmonary hypertension].
Topics: Acetylcholine; Amino Alcohols; Carbachol; Child; Diazepam; Diazoxide; Female; Humans; Hypertension, | 1970 |
Reactive pulmonary arterial hypertension after pulmonary venous constriction in the calf.
Topics: Acetylcholine; Animals; Blood Pressure; Carbon Dioxide; Cardiac Catheterization; Cardiac Output; Cat | 1972 |
[Studies on the etiology of primary pulmonary hypertension in animal experiments].
Topics: Animals; Appetite Depressants; Blood Pressure; Dogs; Hypertension, Pulmonary; Isoproterenol; Oxazole | 1969 |
Primary pulmonary hypertension in a child. Response to pharmacologic agents.
Topics: Acetylcholine; Blood Pressure; Cardiac Catheterization; Cardiac Output; Child; Heart Ventricles; Hex | 1969 |
[The aludrine test: simulation of physical stress in the examination of children with congenital heart defects].
Topics: Adolescent; Aortic Valve Stenosis; Cardiac Catheterization; Cardiac Output; Cardiac Surgical Procedu | 1965 |